Медико-биологический
информационный портал
для специалистов
 
БИОМЕДИЦИНСКИЙ ЖУРНАЛ Medline.ru

СОДЕРЖАНИЕ ЖУРНАЛА:
Физико-химическая биология

Клиническая медицина

Профилактическая медицина

Медико-биологические науки


АРХИВ:

Фундаментальные исследования

Организация здравохраниения

История медицины и биологии



Последние публикации

Поиск публикаций

Articles

Архив :  2000 г.  2001 г.  2002 г. 
               2003 г.  2004 г.  2005 г. 
               2006 г.  2007 г.  2008 г. 
               2009 г.  2010 г.  2011 г. 
               2012 г.  2013 г.  2014 г. 
               2015 г.  2016 г.  2017 г. 
               2018 г.  2019 г.  2020 г. 

Редакционная информация:
        Опубликовать статью
        Наша статистика


 РЕДАКЦИЯ:
Главный редактор

Заместители главного редактора

Члены редколлегии
Специализированные редколлегии


 УЧРЕДИТЕЛИ:
Федеральное государственное бюджетное учреждение науки
"Институт токсикологии Федерального медико-биологического агентства"
(ФГБУН ИТ ФМБА России)

Институт теоретической и экспериментальной биофизики Российской академии наук.

ООО "ИЦ КОМКОН".




Адрес редакции и реквизиты

199406, Санкт-Петербург, ул.Гаванская, д. 49, корп.2

ISSN 1999-6314

Российская поисковая система
Искать: 


«
Vol. 21, Art. 22 (pp. 246-270)    |    2020       
»

Perspective directions of pharmacological prevention and early therapy of radiation damage (review of foreign literature)
Federal State Unitary Enterprise Research & Production Center "Pharmaceutical Protection" of Federal Medical Biological Agency



Brief summary

Based on the analysis of literature data, foreign directions of the development of medicaments for the prevention and early treatment of radiation injuries are considered. The general characteristics of seven radio transmitters that have received status are given IND (investigational new drug - new drug) Food and Drug Administration of the USA: 5-androstenediol (Neumune?), beclomethasone (OrbeShield?), genistein (BIO 300?), granulocyte colony stimulating factor filgrastim (Neupogen?), kinase inhibitor ON01210 (Ex-RAD?), recombinant human interleukin-12 (HemaMax?), flagellin (Entolimod ?). Further experimental and clinical evaluation of their efficacy and safety, licensing as anti-radiation drugs, as well as the search for promising radiomitigators among radiation-induced apoptosis inhibitors and ligands for modulating intracellular signaling pathways determines the strategy for the development of pharmacological prophylaxis and early treatment of radiation injuries.


Key words

ionizing radiation, radiation injury, radiation countermeasures, radiomitigators.





(The article in PDF format. For preview need Adobe Acrobat Reader)



Open article in new window

Reference list

1. Grebenuk A.N., Gladkih V.D. Sovremennoe sostoyanie i perspektivi razrabotki lekarstvennih sredstv dlya profilaktiki i rannei terapii radiacionnih porajenii / Radiacionnaya biologiya. Radioekologiya. 2019. tom 59. N 2. S. 132-149.


2. Sostoyanie i perspektivi razvitiya sredstv profilaktiki i lecheniya radiacionnih porajenii. Red. V.D. Gladkih. M.: Kommentarii, 2016. 304 s.


3. Tarymov R.A., Grebenuk A.N., Basharin V.A. Biologicheskie svoistva fitoestrogena genisteina (obzor literatyri) / Med. ekstrem. sityacii. 2014. N 2. S. 55-68.


4. Finashov L.V., Rafikov Y.M. Analiz literatyrnih dannih o perspektivnih radioprotektorah, razrabotannih v Soedinennih Shtatah Ameriki / Vopr. radiac. bezopasnosti. 2017. N 2 (86). S. 75-81.


5. Ahmad I.U., Forman J.D., Sarkar F.H. Soy isoflavones in conjunction with radiation therapy in patients with prostate cancer / Nutr. Cancer. 2010. Vol. 62, N 7. P. 996-1000.


6. Ariyasu S., Sawa A., Morita A. Design and synthesis of 8-hydroxyquinoline-based radioprotective agents / Bioorg. Med. Chem. 2014. Vol. 22, N 1. P. 3891-3905.


7. Basile L.A., Ellefson D., Gluzman-Poltorak Z. HemaMax, a recombinant human interleukin-12, is a potent mitigator of acute radiation injury in mice and non-human primates / PLoS One. 2012. Vol. 7, N 2. doi: .10.1371/journal.pone.0030434


8. Burdelya L.G., Brackett C.M., Kojouharov B. Central role of liver in anticancer and radioprotective activities of Toll-like receptor 5 agonist / Proc. Natl. Acad. Sci. USA. 2013. Vol. 110, N 20. P. 1857-1866


9. Burdelya L.G., Krivokrysenko V.I., Tallant T.C. Anagonist of toll-like receptor 5 has radioprotective activity in mouse and primate models / Science. 2008. Vol. 320, N 5873. P. 226-230.


10. Casey-Sawicki K. Zhang M, Kim S. et al. A basic fibroblast growth factor analog for protection and mitigation against acute radiation syndromes / Health Phys. 2014. Vol. 106, N 6. R. 704-712.


11. Chen J.K., Li Z.P., Liu Y.Z. Activation of alpha 7 nicotinic acetylcholine receptor protects mice from radiation-induced intestinal injury and mortality / Radiat. Res. 2014. Vol. 181, N 6. P. 666-671.


12. Compadre C.M., Singh A., Thakkar S. Molecular dynamics guided design of tocof1exol: a new radioprotectant tocotrienol with enhanced bioavailability / Drug Dev. Res. 2014. Vol. 75, N 1. P. 10-22.


13. Davis T.A., Clarke T.K., Mog S.R., Landauer M.R. Subcutaneous administration of genistein prior to lethal irradiation supports multilineage, hematopoietic progenitor cell recovery and survival / Int. J. Radiat. Biol.2007. Vol. 83, N 3. P. 141-151.


14. Davis T.A., Mungunsukh O., Zins S. Genistein induces radioprotection by hematopoietic stem cell quiescence / Int. J. Radiat. Biol. 2008. Vol. 84, N 9. P. 713-726.


15. Fuccio L., Guido A., Laterza L. et al. Randomised clinical trial: preventive treatment with topical rectal beclomethasone dipropionate reduces post-radiation risk of bleeding in patients irradiated for prostate cancer / Aliment. Pharm. Ther. 2011. Vol. 34, N 6. P. 628-637.


16. Ganai A.A., Farooqi H. Bioactivity of genistein: A review of in vitro and in vivo studies / Biomed. Pharmacother. 2015. Vol. 76. P. 30-38.


17. Georges G.E., Kuver R.P., Jordan R. Post-exposure oral 17,21-beclomethasone dipropionate (BDP) improves survival in a canine gastrointestinal acute radiation syndrome (GI-ARS) model / 58th Annual Meeting of the Radiation Research Society. San Juan: Lawrence, KS: Radiation Research Society, 2012.


18. Gerber S. A., Cummings R.J, Judge J.L. et al. Il-12 preserves the cutaneous physical and immunological varrier after radiation exposure / Radiat. Res. 2015. Vol. 183, R.72-81.


19. Ghosh S.P., Kulkarni S., Perkins M.W. Amelioration of radiation-induced hematopoietic and gastrointestinal damage by Ex-RAD(R) in mice / J. Radiat. Res. 2012. Vol. 53, N 4. P. 526-536.


20. Ghosh S.P., Perkins M.W., Hieber K. Radiation protection by a new chemical entity, Ex-Rad: efficacy and mechanisms / Radiat. Res. 2009. Vol. 171, N 2. P. 173-179.


21. Gluzman-Poltorak Z., Mendonca S.R., Vainstein V. Randomized comparison of single dose of recombinant human IL-12 versus placebo for restoration of hematopoiesis and improved survival in rhesus monkeys exposed to lethal radiation / J. Hematol. Oncol. 2014. Vol. 7. P. 31.


22. Gluzman-Poltorak Z., Vainstein V., Basile L.A. Association of hematological nadirs and survival in a nonhumanprimate model of hematopoietic syndrome of acute radiation syndrome / Radiat. Res. 2015. Vol. 184. P. 226-230.


23. Gluzman-Poltorak Z., Vainstein V., Basile L.A. Recombinant interleukin-12, but not granulocyte-colony stimulating factor, improves survival in lethally irradiated nonhuman primates in the absence of supportive care: evidence for the development of a frontline radiation medical countermeasure / Am. J. Hematol. 2014. Vol. 89. P. 868-873.


24. Grace M.B., Blakely W.F., Landauer M.R. Genisteininduced alterations of radiation-responsive gene expression / Radiat. Meas. 2007. V. 42. Is. 6-7. P. 1152-1157.


25. Grace M.B., Singh V.K., Rhee J.G. 5-AED enhances survival of irradiated mice in a G-CSF-dependent manner, stimulates innate immune cell function, reduces radiation-induced DNA damage and induces genes that modulate cell cycle progression and apoptosis / J. Radiat. Res. 2012. Vol. 53, N 6. P. 840-853.


26. Grebenyuk A.N., Gladkikh V.D. Modern condition and prospects for the development of medicines towards prevention and early treatment of radiation damage / Biol. Bull. 2019. Vol. 46, N. 11. R. 1540-1555.


27. Goldman D.C., Alexeev V., Lash E., Guha C., Rodeck U., Fleming W.H. The Triterpenoid RTA 408 is a Robust Mitigator of Hematopoietic Acute Radiation Syndrome in Mice / Radiat. Res. 2015. Vol. 183, N 3. R. 338-44.


28. Hauer-Jensen M. Toward development of interleukin-11 as a medical countermeasure for use in radiological/nuclear emergencies / Dig. Dis. Sci. 2014. Vol. 59, N7. R.1349-1351.


29. Herodin F., Bourin P., Mayol J.-F. Short-term injection of antiapoptotic cytokine combinations soon after lethal γ-irradiation promotes survival / Blood. 2003. Vol. 101, N 7. P. 2609-2616.


30. Hofer M., Hoferova Z., Falk M. Pharmacological modulation of radiation damage. Does it exist a chance for other substances than hematopoietic growth factors and cytokines? / Int. J. Mol. Sci. 2017. Vol. 18, N 7. doi: 10.3390/ijms18071385


31. Kang A.D., Cosenza S.C., Bonagura M. et al. ON01210.Na (Ex-RAD?) mitigates radiation damage through activation of the AKT pathway / PLoS One. 2013. Vol. 8, N 3. doi: 10.1371/journal. pone.0058355


32. Kim J.S., Jang W.S., Lee S. A study of the effect of sequential injection of 5-androstenediol on irradiationinduced myelosuppression in mice / Arch. Pharm. Res. 2015. Vol. 38, N 6. P. 1213-1222.


33. Kim J., Thimmulappa R.K., Kumar V. et al. NRF2-mediated Notch pathway activation enhances hematopoietic reconstitution following myelosuppressive radiation / J. Clin. Invest. 2014. Vol. 124, N 2. P. 730-741.


34. Krivokrysenko V.I., Toshkov I.A., Gleiberman A.S. The Toll-like receptor 5 agonist Entolimod mitigates lethal acute radiation syndrome in non-human primates / PLoS One. 2015. Vol. 10, N 9. doi: 10.1371/journal.pone.0135388


35. Krivokrysenko V.I., Shakhov A.N., Singh V.K. Identification of granulocyte colony-stimulating factor and interleukin-6 as candidate biomarkers of CBLB502 efficacy as a medical radiation countermeasure / J. Pharmacol. Exp. Ther. 2012. Vol. 343, N 2. P. 497-508.


36. Landauer M.R., Srinivasan V., Seed T.M. Genistein treatment protects mice from ionizing radiation injury / J. Appl. Toxicol. 2003. Vol. 23, N 6. P. 379-385.


37. Lee C.L., Lento W.E., Castle K.D. Inhibiting glycogen synthase kinase-3 mitigates the hematopoietic acute radiation syndrome in mice / Radiat. Res. 2014. Vol. 181, N 5. P. 445-451.


38. Li H.N., Ha C.T., Fu D., Landauer M.R., Ghosh S.P., Xiao M. Delta-tocotrienol suppresses radiation-induced microRNA-30 and protects mice and human CD34+ cells from radiation injury// PLoS One. 2015. Vol. 10, N 3.


39. Miller R.C., Murley J.S, Grdina D. J. Metformin Exhibits Radiation Countermeasures Efficacy When Used Alone or in Combination with Sulfhydryl Containing Drugs / Radiat. Res. 2014. V. 181. R. 464-470.


40. Mirzoeva S. Paunesku T., Wanzer M.B., Shirvan A., Kaempfer R., Woloschak G.E., Small W. Single administration of r2TA (AV103), a CD28 antagonist peptide, prevents inflammatory and thrombotic reactions and protects against gastrointestinal injury in total-body irradiated mice / PLoS One. 2014. Vol. 9, N 7.


41. Morita A., Ariyasu S., Wang B. AS-2, a novel inhibitor of p53-dependent apoptosis, prevents apoptotic mitochondrial dysfunction in a transcription-independent manner and protects mice from a lethal dose of ionizing radiation / Biochem. Biophys. Res. Commun. 2014. Vol. 450, N 4. P. 1498-1504.


42. NIH Strategic Plan and Research Agenda for Medical Countermeasures Against Radiological and Nuclear Threats / U.S. Department of Health and Human Services. NIH Publication No. 05-5608, 2005.


43. Neelis K.J., Dubbelman Y.D., Qingliang L. Simultaneous administration of TPO and G-CSF after cytoreductive treatment of Rhesus monkeys prevents thrombocytopenia, accelerates platelet and reconstitution, alleviates neutropenia, and promotes the recovery of immature bone marrow cells / Exp. Hematol. 1997. Vol. 25, N 10. P. 1084-1093.


44. Neelis K.J., Hartong S.C., Egeland T. The efficacy of single dose administration of thrombopoietin with co-administration of either granulocyte / macrophage or granulocyte colony stimulated factor in myelosuppressed Rhesus monkeys / Blood. 1997. Vol. 90, N 7. P. 2565-2573.


45. Pathak R. Shao L., Hauer-Jensen M. Thrombomodulin contributes to gamma tocotrienol-mediated lethality protection and hematopoietic sell recovery in irradiated mice / PLoS One. 2015. Vol. 10. N 4.


46. Rosen E.M., Day R., Singh V.K. New approaches to radiation protection / Front. Oncol. 2015. Vol. 4. Article 381. 15 r.


47. Satyamitra M., Lombardini E., Graves J. A TPO receptor agonist, ALXN4100TPO, mitigates radiation-induced lethality and stimulates hematopoiesis in CD2F1 mice / Radiat. Res. 2011. V. 175, N 6. P. 746-758.


48. Shukla P.N., Gairola M., Mohanti B.K., Rath G.K. Prophylactic beclomethasone spray to the skin during postoperative radiotherapy of carcinoma breast: a prospective randomized study / Indian J. Cancer. 2006. Vol. 43, N 4. P. 180-184.


49. Singh V.K., Beattie L.A., Seed T.M. Vitamin E: tocopherols and tocotrienols as potential radiation countermeasures / J. Radiat. Res. 2013. Vol. 54, N 6. P. 973-988.


50. Singh V.K., Grace M.B., Jacobsen K.O. Administration of 5-androstenediol to mice: pharmacokinetics and cytokine gene expression / Exp. Mol. Pathol. 2008. Vol. 84, N 2. P. 178-188.


51. Singh P.K., Wise S.Y., Ducey E.J. α-Tocopherol succinate protects mice against radiation-induced gastrointestinal injury / Radiat. Res. 2012. Vol. 177, N 2. P. 133-145


52. Singh V.K., Newman V.L., Romaine P.L. Radiation countermeasure agents: an update (2011-2014) / Expert. Opin. Ther. Pat. 2014. Vol. 24, N 11. P. 1229-1255.


53. Singh V.K., Newman V.L., Seed T.M. Colony-stimulating factors for the treatment of the hematopoietic component of the acute radiation syndrome (H-ARS): a review / Cytokine. 2014. Vol. 71, N 1. P. 22-37.


54.Singh V. K., Romaine P.L., Newman V.L., Seed T.M. Tocols induce G-CSF and mobilise progenitors that mitigate radiation injury / Radiat. Prot. Dosimetry. 2014. Vol. 162, N. 1-2. R.83-87.


55. Singh V.K., Romaine P.L., Newman V.L. Biologics as countermeasures for acute radiation syndrome: where are we now? / Expert. Opin. Biol. Ther. 2015. Vol. 15, N 4. P. 465-471.


56. Singh V.K., Romaine P.L., Seed T.M. Medical countermeasures for radiation exposure and related injuries: characterization of medicines, FDA-approval status and inclusion into the Strategic National Stockpile / Health Phys. 2015. Vol. 108, N 6. P. 607-630.


57. Singh V.K., Romaine P.L., Newman V.L., Seed T.M. Medical countermeasures for unwanted CBRN exposures: part II radiological and nuclear threats with review of recent countermeasure patents / Expert. Opin. Ther. Pat. 2016. Vol. 26, N 12. P. 1399-1408.


58. Singh V.K., Hanlon B.K., Santiago P.T., Seed T.M. A review of radiation countermeasures focusing on injuryspecific medicinals and regulatory approval status: part III. Countermeasures under early stages of development along with 'standard of care' medicinal and procedures not requiring regulatory approval for use / Int. J. Radiat. Biol. 2017. Vol. 93, N 9. P. 885-906.


59. Singh V.K., Seed T.M. A review of radiation countermeasures focusing on injury-specific medicinals and regulatory approval status: part I. Radiation sub-syndromes, animal models and FDA-approved counter measures / Int. J. Radiat. Biol. 2017. Vol. 93, N 9. P. 851-869.


60.Sridharan V,. Tripathi P., Aykin-Burns N., Krager K.J., Sharma S.K., Moros E.G. Tocotrienol-Enriched Formulation Rrotects against Radiation-Induced Changes in Cardiac Mitochondria without Modifying Late Cardiac Function or Structure / Rad. Res. 2015. Vol.183, N 3. R. 357-366.


61. Stickney D.R., Dowding C., Garsd A. 5-androstenediol stimulates multilineage hematopoiesis in rhesus monkeys with radiation-induced myelosuppression / Int. Immunopharmacol. 2006. Vol. 6, N 11. P. 1706-1713.


62. Suman S., Datta K., Doiron K. Radioprotective effects of ON 01210.Na upon oral administration / J. Radiat. Res. 2012. Vol. 3, N 3. P. 368-376.


63. Suman S., Maniar M., Fornace A.J., Datta K. Administration of ON 01210.Na after exposure to ionizing radiation protects bone marrow cells by attenuating DNA damage response / Radiat. Oncol. 2012. Vol. 7. P. 6. doi: 10.1186/1748-717X-7-6


64. Tacyildiz N., Ozyoruk D., Yavuz G. Soy isoflavones ameliorate the adverse effects of chemotherapy in children // Nutr. Cancer. 2010. Vol. 62, N 7. P. 1001-1005.


65. Wang C., Zhang B., Wang S. Recombinant human thrombopoietin promotes hematopoietic reconstruction after severe whole body irradiation / Sci. Rep. 2015. N 5. P. 12-24.


66. Weiss J.F., Landauer M.R. Protection against ionizing radiation by antioxidant nutrients and phytochemicals / Toxicol. 2003. Vol. 189, N 1-2. P. 1-20.


67. Weiss J.F., Landauer M.R. History and development of radiation-protective agents / Int. J. Radiat. Biol. 2009. Vol. 85, N 7. P. 539-573.


68. Whitnall M.H., Elliott T.B., Harding R.A. Androstenediol stimulates myelopoiesis and enhances resistance to infection in gamma-irradiated mice / Int. J. Immunopharmacol. 2000. Vol. 22, N 1. P. 1-14.


69. Whitnall M.H., Villa V., Seed T.M. Molecular specificity of 5-androstenediol as a systemic radioprotectant in mice / Immunopharmacol. Immunotoxicol. 2005. Vol. 27, N 1. P. 15-32.


70. Whitnall M.H., Wilhelmsen C.L., McKinney L.-A. Radioprotective efficacy and acute toxicity of 5-androstenediol after subcutaneous or oral administration in mice / Immunopharmacol. Immunotoxicol. 2002. Vol. 24, N 4. P. 596-626.


71. Xiao M., Inal C.E., Parekh V.I. 5-Androstenediol promotes survival of gamma-irradiated human hematopoietic progenitors through induction of nuclear factor kappaB activation and granulocyte colony-stimulating factor expression / Mol. Pharmacol. 2007. Vol. 72, N 2. P. 370-379.


72. Yoon S.I., Kurnasov O., Natarajan V. Structural basis of TLR5-flagellin recognition and signaling / Science. 2012. Vol. 335, N 6070. P. 859-864.


73. Zhou Y., Mi M.T. Genistein stimulates hematopoiesis and increases survival in irradiated mice / J. Radiat. Res. 2005. Vol. 46, N 4. P. 425-433.





Свидетельство о регистрации сетевого электронного научного издания N 077 от 29.11.2006
Журнал основан 16 ноября 2000г.
Выдано Министерством РФ по делам печати, телерадиовещания и средств массовых коммуникаций
(c) Перепечатка материалов сайта Medline.Ru возможна только с письменного разрешения редакции

Размещение рекламы

Rambler's Top100